CONTACT US
Home > Inhibitors/Agonists> > Indacaterol
312753-06-3-Indacaterol Indacaterol

Indacaterol

For research use only. Not for therapeutic Use.

  • CAT Number: I003102
  • CAS Number: 312753-06-3
  • Molecular Formula: C24H28N2O3
  • Molecular Weight: 392.499
  • Purity: ≥95%
Inquiry Now
Related products:

Indacaterol (CAT: I003102) is a long-acting beta-2 adrenergic agonist (LABA) used in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It works by relaxing the smooth muscles in the airways, which helps to improve breathing and reduce symptoms such as shortness of breath, wheezing, and coughing. Indacaterol is typically administered via inhalation, providing a sustained bronchodilatory effect that lasts for 24 hours. It is known for its rapid onset of action and favorable safety profile. Indacaterol has been shown to improve lung function, reduce exacerbations, and enhance the overall quality of life in patients with COPD and asthma.


Catalog Number I003102
CAS Number 312753-06-3
Synonyms

5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one

Molecular Formula C24H28N2O3
Purity ≥95%
Target Neuronal Signaling
Solubility 10 mM in DMSO
Storage Store at 0-8°C
Related CAS 753498-25-8 (malate salt)    
IUPAC Name 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
InChI InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1
InChIKey QZZUEBNBZAPZLX-QFIPXVFZSA-N
SMILES CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC
Reference

<br />
1:The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R.Int J Chron Obstruct Pulmon Dis. 2017 May 4;12:1325-1337. doi: 10.2147/COPD.S133307. eCollection 2017. PMID: 28496316 Free PMC Article<br />
2:Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium. Ficker JH, Rabe KF, Welte T.Pulm Pharmacol Ther. 2017 Apr 4. pii: S1094-5539(17)30031-7. doi: 10.1016/j.pupt.2017.04.002. [Epub ahead of print] Review. PMID: 28389258 Free Article<br />
3:Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes. Namba Y, Togo S, Tulafu M, Kadoya K, Nagahama KY, Taka H, Kaga N, Orimo A, Liu X, Takahashi K.Respir Res. 2017 Mar 11;18(1):46. doi: 10.1186/s12931-017-0529-6. PMID: 28284212 Free PMC Article<br />
4:Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial. Rhee CK, Park HY, Park JW, Lee JH, Kim TH, Lee SW, Jung JY, Kim S, Hwang YI, Jung KS.Trials. 2017 Feb 22;18(1):80. doi: 10.1186/s13063-017-1800-3. PMID: 28228162 Free PMC Article<br />
5:Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D.Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:339-349. doi: 10.2147/COPD.S125058. eCollection 2017. PMID: 28176893 Free PMC Article<br />
6:Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease. Burgel PR, Le Gros V, Decuypère L, Bourdeix I, Perez T, Deslée G.BMC Pulm Med. 2017 Jan 31;17(1):25. doi: 10.1186/s12890-017-0372-z. PMID: 28143447 Free PMC Article<br />
7:Erratum: Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study [Corrigendum]. [No authors listed]Int J Chron Obstruct Pulmon Dis. 2017 Jan 10;12:231. doi: 10.2147/COPD.S127610. eCollection 2017. PMID: 28138232 Free PMC Article<br />
8:Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea. Yum HK, Kim HR, Chang YS, Shin KC, Kim S, Oh YM.Tuberc Respir Dis (Seoul). 2017 Jan;80(1):52-59. doi: 10.4046/trd.2017.80.1.52. Epub 2016 Dec 30. PMID: 28119747 Free PMC Article<br />
9:Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study. Salomon J, Stolz D, Domenighetti G, Frey JG, Turk AJ, Azzola A, Sigrist T, Fitting JW, Schmidt U, Geiser T, Wild C, Kostikas K, Clemens A, Brutsche M.Respir Res. 2017 Jan 11;18(1):13. doi: 10.1186/s12931-016-0498-1. PMID: 28077140 Free PMC Article<br />
10:Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis. Vogelmeier C, Zhong N, Humphries MJ, Mezzi K, Fogel R, Bader G, Patalano F, Banerji D.Int J Chron Obstruct Pulmon Dis. 2016 Dec 14;11:3189-3197. doi: 10.2147/COPD.S116786. eCollection 2016. PMID: 28008244 Free PMC Article

Request a Quote